-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Studies have shown that early use of tumor necrosis factor (TNF) antagonists and azathioprine in patients with Crohn’s disease (CD) can achieve clinical remission and endoscopy without corticosteroids more effectively than TNF antagonists alone.
Studies have shown that early use of tumor necrosis factor (TNF) antagonists and azathioprine in patients with Crohn’s disease (CD) can achieve clinical remission and endoscopy without corticosteroids more effectively than TNF antagonists alone.
Researchers retrospectively collected clinical data of patients receiving combination therapy (ECI) and conventional therapy (CM).
Among the 1969 CD patients, 435 had isolated colonic CD (ECI n = 257, CM n = 178), and 1534 had ileal CD (ECI n = 817, CM n = 717).
Figure: The response of different lesions to different therapies
This study found that early TNF antagonists combined with immunosuppressive (ECI) therapy has a better effect on reducing the risk of disease-related complications in CD patients whose lesions are in the colon.
This study found that early TNF antagonists combined with immunosuppressive (ECI) therapy has a better effect on reducing the risk of disease-related complications in CD patients whose lesions are in the colon.
Original source:
Parambir S Dulai.
oup.
Leave a message here
